These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

Sanofi’s teplizumab, which is already FDA-approved to delay the onset of stage 3 type 1 diabetes, has been included on the ...

The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the ...

France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the ADC ...

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

EMD Serono has partnered the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies.